Navigation Links
New Report on 633 Biotechnology Medicines Under Development Released in Michigan

DETROIT, Sept. 24 /PRNewswire-USNewswire/ -- As the nation combats an alarming rise in chronic diseases, the Pharmaceutical Research and Manufacturers of America (PhRMA) today released a new report on the next generation of medicines in research pipelines that offer hope to millions of patients.

The report found that America's pharmaceutical research and biotechnology companies - including several located in Michigan - are testing a record 633 new biotech medicines.

Today's report was released in Michigan due to the growing prominence of the state's biotech sector in developing and testing cutting-edge medicines. Michigan's life sciences industry has become one of the nation's fastest-growing regions, with 112 new biotechnology companies formed in the state since 2000 - including a number of companies that research and develop new medicines.

"The biotechnology revolution is helping create medicines that use unprecedented technologies, such as nano-sized particles that seek out and kill viruses, ways to actually regenerate healthy muscle to replace damaged heart tissue, and gene therapy," said PhRMA Senior Vice President Ken Johnson. "The impact of this research is felt worldwide. Such critical innovation is creating medicines with the potential to help millions of patients live longer, healthier and more productive lives."

"We are proud of the increasingly important role of Michigan's pharmaceutical biotechnology sector in developing and testing cutting-edge medicines," said Stephen Rapundalo, Ph.D., president of MichBio, the association for Michigan's biosciences industry. "MichBio is committed to providing new hope for patients and to driving the continued growth of Michigan's life sciences industry that makes this possible."

All of the experimental medicines in the report are being tested in human clinical trials or await approval by the U.S. Food and Drug Administration.

The 633 biotechnology medicines being developed by companies nationwide include 254 medicines for cancer, 162 for infectious diseases, 59 for autoimmune diseases, 34 for HIV/AIDS and related conditions, 25 for cardiovascular disease, and 19 for diabetes and related conditions. The medicines include a number of innovative approaches, such as a laboratory-made version of a naturally-occurring protein that neutralizes foreign invaders.

Among new biotech medicines that Michigan companies are working on:

-- A treatment to repair damaged neural tissue in patients with spinal cord injuries

-- A medicine that treats the effects of anthrax after toxins have been released into the body, a condition for which there is no approved therapy

-- A treatment for menopause that mimics estrogen's beneficial action in bone tissue

"Researchers are making exciting progress in the search for new cures and treatments for a wide array of serious diseases. But these efforts are wasted if the medicines that are developed are not accessible to the patients who need them," said PhRMA President and CEO Billy Tauzin.

Help is available to patients in need through the Partnership for Prescription Assistance (PPA), a program sponsored by America's pharmaceutical research companies. To date, the PPA has helped more than 5 million patients nationwide, including more than 176,087 people in Michigan. Since its launch in April 2005, the PPA bus tour has visited all 50 states and more than 2,000 cities. The PPA bus has been to Michigan nine times since the program was launched.

To read the 2008 report, Medicines in Development Biotechnology, go to:

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $44.5 billion in 2007 in discovering and developing new medicines. Industry-wide research and investment reached a record $58.8 billion in 2007.

PhRMA Internet Address:

For information on stories of hope and survival, visit:

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For information on the danger of imported drugs, visit:

SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neogen Reports 26% Increase in Revenues
2. Sangui Bio Tech International Inc. Shareholders Meeting Delayed to Include FY 2008 Report
3. MIGENIX Reports First Quarter Fiscal 2009 Financial Results
4. Friends of the Earth Report on Biofuel Production Offers Incomplete, Outdated and Inaccurate Picture, According to Brazilian Sugarcane Industry Association
5. Long-Term Investments Remain Critical to Biotechnology Industry Growth, According to a New Report by Global Industry Analysts
6. Biotechnology & Drug Discovery Markets Push Up Demand for Lab Automation Products, According to a New Report by Global Industry Analysts
7. Injectable CTM Manufacturing Market Report Now Available
8. ThermoGenesis Reports Record Quarterly Revenues of $7.2 Million; Full Year Revenues Increase 31 Percent
9. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
10. Sangui BioTech International, Inc. Files Remaining Reports
11. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... be speaking at the following conference, and invited investors ... York, NY      Tuesday, December 1, 2015 at ... York, NY      Tuesday, December 1, 2015 at ... Healthcare Conference, New York, NY ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... the year and one of the premier annual events for pharmaceutical manufacturing: 2015 ... 8–11 November 2015, where ISPE hosted the largest number of attendees in more ...
(Date:11/24/2015)... ... 2015 , ... This fall, global software solutions leader SAP and AdVenture Capital ... and pitch their BIG ideas to improve health and wellness in their schools. , ... win the title of SAP's Teen Innovator, an all-expenses paid trip to Super Bowl ...
(Date:11/24/2015)... 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its ... at 11:00 a.m. Israel time, at the law ... Allon Street, 36 th Floor, Tel Aviv, Israel ... and Izhak Tamir to the Board of Directors; ... directors; , approval of an amendment to certain terms of options ...
Breaking Biology Technology:
(Date:11/17/2015)... -- Vigilant Solutions announces today that Mr. Dick W. ... --> --> Mr. Boyce ... at TPG Capital, one of the largest global investment ... revenue.  He founded and led TPG,s Operating Group, which ... 1997 to 2013.  In his first role, he served ...
(Date:11/12/2015)...  Arxspan has entered into an agreement with ... use of its ArxLab cloud-based suite of biological ... will support the institute,s efforts to electronically manage ... internally and with external collaborators. The ArxLab suite ... Institute,s electronic laboratory notebook, compound and assay registration, ...
(Date:11/10/2015)... YORK , Nov. 10, 2015 ... to behavioral biometrics that helps to identify and ... fraud. Signature is considered as the secure and ... the identification of a particular individual because each ... more accurate results especially when dynamic signature of ...
Breaking Biology News(10 mins):